MA49625A - Compositions pharmaceutiques - Google Patents

Compositions pharmaceutiques

Info

Publication number: MA49625A
Authority: MA; Morocco
Prior art keywords: pharmaceutical compositions; pharmaceutical; compositions
Prior art date: 2017-07-17

Application number

MA049625A

Other languages

English (en)

Inventor

Matthew Carl Allgeier

Tony Yantao Zhang

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-07-17

Filing date

2018-07-10

Publication date

2020-05-27

2018-07-10 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2020-05-27 Publication of MA49625A publication Critical patent/MA49625A/fr

Links

239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

MA049625A 2017-07-17 2018-07-10 Compositions pharmaceutiques MA49625A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201762533332P	2017-07-17	2017-07-17
US201762538936P	2017-07-31	2017-07-31

Publications (1)

Publication Number	Publication Date
MA49625A true MA49625A (fr)	2020-05-27

Family

ID=63036446

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA049625A MA49625A (fr)	2017-07-17	2018-07-10	Compositions pharmaceutiques

Country Status (25)

Country	Link
US (2)	US11376223B2 (fr)
EP (1)	EP3654955B1 (fr)
JP (1)	JP6854384B2 (fr)
KR (1)	KR102409102B1 (fr)
CN (1)	CN110913843B (fr)
AU (1)	AU2018301924B2 (fr)
BR (1)	BR112019028278A2 (fr)
CA (1)	CA3069948C (fr)
CL (1)	CL2020000120A1 (fr)
CO (1)	CO2019015099A2 (fr)
CR (1)	CR20190577A (fr)
DO (1)	DOP2020000010A (fr)
EC (1)	ECSP20003493A (fr)
ES (1)	ES3032318T3 (fr)
IL (1)	IL272044A (fr)
JO (2)	JOP20200005B1 (fr)
MA (1)	MA49625A (fr)
MY (1)	MY198062A (fr)
PE (1)	PE20200174A1 (fr)
PH (1)	PH12020500120A1 (fr)
SA (1)	SA520410976B1 (fr)
SG (1)	SG11201912482WA (fr)
UA (1)	UA125535C2 (fr)
WO (1)	WO2019018155A1 (fr)
ZA (1)	ZA201908550B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR102409102B1 (ko) *	2017-07-17	2022-06-16	일라이 릴리 앤드 캄파니	제약 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2248908T7 (es)	1997-06-06	2014-11-24	Depomed, Inc.	Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
EP1063973B1 (fr)	1998-03-19	2016-11-16	Bristol-Myers Squibb Company	Systeme d'apport a liberation lente biphasique destine a des medicaments a solubilite elevee et procede associe
PE20020617A1 (es) *	2000-08-22	2002-08-05	Novartis Ag	Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
US6723340B2 (en)	2001-10-25	2004-04-20	Depomed, Inc.	Optimal polymer mixtures for gastric retentive tablets
US8329217B2 (en) *	2001-11-06	2012-12-11	Osmotica Kereskedelmi Es Szolgaltato Kft	Dual controlled release dosage form
CA2494916A1 (fr) *	2002-08-08	2004-02-19	Sankyo Company Limited	Composition medicale abaissant le taux de lipides sanguins
US20050013863A1 (en) *	2003-07-18	2005-01-20	Depomed, Inc., A Corporation Of The State Of California	Dual drug dosage forms with improved separation of drugs
JP5467870B2 (ja)	2007-02-09	2014-04-09	アルファファームピーティーワイリミテッド	異なる物理的形態の２種以上の有効医薬成分を含有する投薬形態
US8574625B2 (en) *	2007-05-30	2013-11-05	Wockhardt Ltd.	Tablet dosage form
WO2012010977A2 (fr)	2010-07-21	2012-01-26	Nucitec S.A. De C.V.	Forme pharmaceutique quotidienne unique destinée à la prévention et au traitement du syndrome métabolique
US9572784B2 (en) *	2011-01-07	2017-02-21	Elcelyx Therapeutics, Inc.	Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
CA2866377C (fr) *	2012-03-30	2020-02-11	Daewoong Pharmaceutical Co., Ltd.	Composition pharmaceutique comprenant de l'olmesartan medoxomil et de la rosuvastatine ou son sel
KR20140028971A (ko) *	2012-08-31	2014-03-10	한미약품 주식회사	아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
CN103054856A (zh) *	2012-12-30	2013-04-24	成都恒瑞制药有限公司	含有盐酸二甲双胍和阿托伐他汀钙的固体口服制剂
KR101597004B1 (ko) *	2013-07-25	2016-02-23	씨제이헬스케어 주식회사	서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
BR102013028883A2 (pt)	2013-11-08	2015-10-06	Hypermarcas S A	forma farmacêutica oral para a prevenção de doenças vasculares, comprimido como forma farmacêutica e cápsula gelatinosa como forma farmacêutica
WO2016040462A2 (fr) *	2014-09-09	2016-03-17	ARKAY Therapeutics, LLC	Formulations et méthodes de traitement du syndrome métabolique
KR102409102B1 (ko) *	2017-07-17	2022-06-16	일라이 릴리 앤드 캄파니	제약 조성물

2018
- 2018-07-10 KR KR1020207001147A patent/KR102409102B1/ko active Active
- 2018-07-10 AU AU2018301924A patent/AU2018301924B2/en active Active
- 2018-07-10 EP EP18746471.4A patent/EP3654955B1/fr active Active
- 2018-07-10 US US16/628,101 patent/US11376223B2/en active Active
- 2018-07-10 SG SG11201912482WA patent/SG11201912482WA/en unknown
- 2018-07-10 MA MA049625A patent/MA49625A/fr unknown
- 2018-07-10 PE PE2019002624A patent/PE20200174A1/es unknown
- 2018-07-10 MY MYPI2020000220A patent/MY198062A/en unknown
- 2018-07-10 CA CA3069948A patent/CA3069948C/fr active Active
- 2018-07-10 JP JP2020501527A patent/JP6854384B2/ja active Active
- 2018-07-10 ES ES18746471T patent/ES3032318T3/es active Active
- 2018-07-10 WO PCT/US2018/041378 patent/WO2019018155A1/fr not_active Ceased
- 2018-07-10 CN CN201880047481.8A patent/CN110913843B/zh active Active
- 2018-07-10 UA UAA202000155A patent/UA125535C2/uk unknown
- 2018-07-10 BR BR112019028278-5A patent/BR112019028278A2/pt active Search and Examination
- 2018-07-10 CR CR20190577A patent/CR20190577A/es unknown
2019
- 2019-12-20 ZA ZA2019/08550A patent/ZA201908550B/en unknown
- 2019-12-30 CO CONC2019/0015099A patent/CO2019015099A2/es unknown
2020
- 2020-01-06 SA SA520410976A patent/SA520410976B1/ar unknown
- 2020-01-14 JO JOJO/P/2020/0005A patent/JOP20200005B1/ar active
- 2020-01-14 IL IL272044A patent/IL272044A/en unknown
- 2020-01-15 DO DO2020000010A patent/DOP2020000010A/es unknown
- 2020-01-15 CL CL2020000120A patent/CL2020000120A1/es unknown
- 2020-01-16 PH PH12020500120A patent/PH12020500120A1/en unknown
- 2020-01-17 EC ECSENADI20203493A patent/ECSP20003493A/es unknown
2022
- 2022-06-01 US US17/829,908 patent/US11918692B2/en active Active
2023
- 2023-05-04 JO JOJO/P/2023/0099A patent/JOP20230099A1/ar unknown

Also Published As

Publication number	Publication date
MY198062A (en)	2023-07-31
US11918692B2 (en)	2024-03-05
BR112019028278A2 (pt)	2020-07-14
DOP2020000010A (es)	2020-02-28
PE20200174A1 (es)	2020-01-24
SA520410976B1 (ar)	2023-03-23
ZA201908550B (en)	2024-06-26
EP3654955A1 (fr)	2020-05-27
CA3069948A1 (fr)	2019-01-24
US20210137842A1 (en)	2021-05-13
CN110913843B (zh)	2022-09-13
EP3654955C0 (fr)	2025-05-07
CO2019015099A2 (es)	2020-01-17
KR20200015758A (ko)	2020-02-12
KR102409102B1 (ko)	2022-06-16
SG11201912482WA (en)	2020-02-27
ES3032318T3 (en)	2025-07-17
CN110913843A (zh)	2020-03-24
US20220287978A1 (en)	2022-09-15
PH12020500120A1 (en)	2020-09-28
CA3069948C (fr)	2022-05-17
IL272044A (en)	2020-03-31
US11376223B2 (en)	2022-07-05
NZ760868A (en)	2023-09-29
CL2020000120A1 (es)	2020-07-17
CR20190577A (es)	2020-01-29
ECSP20003493A (es)	2020-08-31
UA125535C2 (uk)	2022-04-13
JOP20200005B1 (ar)	2024-04-18
JP2020527147A (ja)	2020-09-03
WO2019018155A1 (fr)	2019-01-24
JP6854384B2 (ja)	2021-04-07
JOP20200005A1 (ar)	2020-01-14
AU2018301924B2 (en)	2021-07-29
JOP20230099A1 (ar)	2023-05-04
EP3654955B1 (fr)	2025-05-07
AU2018301924A1 (en)	2019-12-19

Publication	Publication Date	Title
DK3529248T3 (da)	2020-09-14	Farmaceutiske sammensætninger
MA50541A (fr)	2021-04-07	Formulations pharmaceutiques
DK3655017T3 (da)	2025-03-31	Farmaceutisk sammensætning
EP3513809A4 (fr)	2020-06-03	Composition médicinale
DK3256138T3 (da)	2022-05-16	Farmaceutiske sammensætninger omfattende meloxicam
EP3641771A4 (fr)	2020-12-16	Compositions pharmaceutiques
MA46867A (fr)	2019-09-25	Formulations pharmaceutiques
MA42303A (fr)	2018-05-09	Formulations pharmaceutiques
EP3316685A4 (fr)	2019-03-13	Compositions pharmaceutiques lyophilisées
DK3634377T3 (da)	2021-08-30	Farmaceutisk formulering
EP3603642A4 (fr)	2020-09-02	Préparation pharmaceutique
MA45187A (fr)	2019-04-10	Combinaisons pharmaceutiques
DK3583943T3 (da)	2024-10-14	Farmaceutisk sammensætning
EP3914234A4 (fr)	2022-09-14	Compositions pharmaceutiques
MA49837A (fr)	2020-06-17	Compositions pharmaceutiques
EP3389633A4 (fr)	2019-08-07	Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine
EP3337463A4 (fr)	2019-04-03	Formulations pharmaceutiques
SMT202400478T1 (it)	2025-01-14	Composizione farmaceutica
EP3646863A4 (fr)	2021-03-24	Composition pharmaceutique
EP3302483A4 (fr)	2019-02-27	Compositions pharmaceutiques et utilisation de celles-ci
EP3727485C0 (fr)	2023-07-26	Composition pharmaceutique
DK3601277T3 (da)	2024-01-15	Farmaceutisk formulering
EP3651800A4 (fr)	2021-04-14	Formulations pharmaceutiques hydrocompressées
EP3423041A4 (fr)	2019-09-11	Compositions pharmaceutiques
EP3706731A4 (fr)	2021-08-18	Formulations améliorées de médicaments